Date published: 2026-4-23

1-800-457-3801

SCBT Portrait Logo
Seach Input

Levosimendan (CAS 141505-33-1)

5.0(1)
Write a reviewAsk a question

Alternate Names:
Simdax; Mesoxalonitrile (−)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6- oxo-3-pyridazinyl)phenyl)hydrazone
Application:
Levosimendan is a Ca2+ sensitizer that increases contractile force of the myocardium
CAS Number:
141505-33-1
Purity:
≥99%
Molecular Weight:
280.28
Molecular Formula:
C14H12N6O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Levosimendan is a Ca2+ sensitizer that increases contractile force of the myocardium by enhancing the sensitivity of myofilaments to calcium without increasing intracellular calcium concentration. Levosimendan has been shown to reduce circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators. Levosimendan is an inhibitor of PDE.


Levosimendan (CAS 141505-33-1) References

Udvary E, Papp JG, Vegh A. Br J Pharmacol. 114:656-61 (1995). Parissis JT, Adamopoulos S, Antoniades C et al. Am J Cardiol. 93:1309-12 (2004). Eriksson O, Pollesello P, Haikala H. J Cardiovasc Pharmacol. 44:316-21 (2004).

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Levosimendan, 100 mg

sc-204792
100 mg
$104.00

Levosimendan, 250 mg

sc-204792A
250 mg
$228.00

What is the appearance of the compound?

Asked by: two2igm05
Thank you for your question. The compound, sc-204792, is provided as a yellow crystalline powder. If you have any further questions or concerns, please feel free to contact our Technical Service department by calling 800-457-3801 option 2, emailing scbt@scbt.com, or using the Live Chat function on our website.
Answered by: Tech Service 8
Date published: 2017-01-24
  • y_2026, m_4, d_23, h_7CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.43
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_204792, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getContent, 103ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from HillestadHillestad, V. et al. (PubMed 24072410) reported that long-term Levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene. -SCBT Publication Review
Date published: 2015-06-16
  • y_2026, m_4, d_23, h_7
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.43
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_204792, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getReviews, 9ms
  • REVIEWS, PRODUCT
Levosimendan is rated 5.0 out of 5 by 1.
  • y_2026, m_4, d_23, h_7
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.43
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_204792, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getAggregateRating, 103ms
  • REVIEWS, PRODUCT